Several pharmaceutical companies presented key findings in skin disease research at the American Academy of Dermatology’s annual conference in Orlando, Florida, according to a March 31 report from BioSpace.
The meeting brought together experts to discuss new data on treatments for conditions such as atopic dermatitis, hidradenitis suppurativa, dermatomyositis and plaque psoriasis. These updates may affect future therapies and regulatory decisions for patients with chronic skin diseases.
Sanofi showcased results from late-stage trials of its anti-OX40L antibody amlitelimab for atopic dermatitis. The company described "progressively increasing efficacy" across its COAST-1, COAST-2 and SHORE studies. However, Leerink Partners analysts said amlitelimab’s efficacy was weaker compared to Dupixent in cross-trial assessments and lowered their sales projections by half following the latest disclosures. "We are reducing our amlitelimab sales projections by 50% following additional data disclosures," Leerink said.
Incyte reported that its oral JAK1 inhibitor povorcitinib maintained response rates through 54 weeks in patients with hidradenitis suppurativa during the Phase 3 STOP-HS1 and STOP-HS2 studies. Up to 71.4% of patients saw significant reductions in lesion counts without increases in abscesses or draining tunnels. William Blair analysts called these results “robust,” but noted commercial questions remain regarding competition with AbbVie’s Rinvoq.
Roivant presented positive data on brepocitinib for dermatomyositis via its Priovant subsidiary. The company highlighted "rapid and statistically significant reductions in itch" as well as improved quality of life over one year. Brepocitinib achieved higher functional skin remission rates among difficult-to-treat patients versus placebo. Analysts from Leerink said these findings "reinforce its compelling profile." The U.S. Food and Drug Administration has accepted an approval application for brepocitinib with a decision expected later this year.
Alumis released Phase 3 results for envudeucitinib, a TYK2 inhibitor tested against plaque psoriasis. At week sixteen, more than half of treated patients showed strong clinical responses compared to less than five percent receiving placebo; full clearance increased further by week twenty-four without major safety concerns reported.
